Geode Capital Management’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-38,820
Closed -$22.5K 4844
2023
Q1
$22.5K Hold
38,820
﹤0.01% 4684
2022
Q4
$27K Sell
38,820
-97
-0.2% -$158 ﹤0.01% 4723
2022
Q3
$108K Hold
38,917
﹤0.01% 4539
2022
Q2
$177K Buy
38,917
+1,157
+3% +$5.08K ﹤0.01% 4346
2022
Q1
$269K Hold
37,760
﹤0.01% 4230
2021
Q4
$254K Hold
37,760
﹤0.01% 4373
2021
Q3
$439K Buy
37,760
+2,424
+7% +$33.5K ﹤0.01% 4094
2021
Q2
$660K Buy
35,336
+23,675
+203% +$441K ﹤0.01% 3809
2021
Q1
$270K Buy
+11,661
New +$295K ﹤0.01% 4021
2019
Q4
Sell
-1,479
Closed -$22K 4238
2019
Q3
$22K Hold
1,479
﹤0.01% 4141
2019
Q2
$36K Hold
1,479
﹤0.01% 4115
2019
Q1
$53K Hold
1,479
﹤0.01% 4016
2018
Q4
$53K Buy
1,479
+763
+107% +$64.3K ﹤0.01% 3981
2018
Q3
$111K Hold
716
﹤0.01% 3907
2018
Q2
$95K Buy
716
+134
+23% +$20.3K ﹤0.01% 3877
2018
Q1
$144K Hold
582
﹤0.01% 3772
2017
Q4
$161K Hold
582
﹤0.01% 3724
2017
Q3
$235K Hold
582
﹤0.01% 3619
2017
Q2
$344K Buy
582
+38
+7% +$22.2K ﹤0.01% 3498
2017
Q1
$334K Buy
544
+269
+98% +$95.7K ﹤0.01% 3473
2016
Q4
$55K Hold
275
﹤0.01% 3898
2016
Q3
$72K Hold
275
﹤0.01% 3874
2016
Q2
$82K Hold
275
﹤0.01% 3844
2016
Q1
$117 Hold
275
﹤0.01% 3794
2015
Q4
$136K Sell
275
-7
-2% -$5.06K ﹤0.01% 3799
2015
Q3
$330K Buy
282
+1
+0.4% +$1.53K ﹤0.01% 3441
2015
Q2
$496K Buy
281
+15
+6% +$23.3K ﹤0.01% 3204
2015
Q1
$312K Hold
266
﹤0.01% 3407
2014
Q4
$266K Buy
266
+1
+0.4% +$1K ﹤0.01% 3471
2014
Q3
$358K Hold
265
﹤0.01% 3315
2014
Q2
$448K Hold
265
﹤0.01% 3217
2014
Q1
$599K Buy
265
+79
+42% +$202K ﹤0.01% 3067
2013
Q4
$384K Buy
186
+111
+148% +$240K ﹤0.01% 3193
2013
Q3
$229K Buy
+75
New +$128K ﹤0.01% 3261

Other funds holding VYNT

Geode Capital Management's VYNT Position: Q2 2023 in Review

Geode Capital Management sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2023, closing a stake of 38,820 shares — an estimated $22.5K sold.

Geode Capital Management first reported a position in VYNT in Q3 2013 and held it in 34 quarters. The position peaked at $660K in Q2 2021. 1 fund tracked by Wall St. Rank holds VYNT as of Q2 2023.

  • Geode Capital Management reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Geode Capital Management sold 38,820 Vyant Bio, Inc. Common Stock shares in Q2 2023, an estimated $22.5K.
  • Geode Capital Management first reported a position in Vyant Bio, Inc. Common Stock in Q3 2013 and held it in 34 quarters.
  • Geode Capital Management's Vyant Bio, Inc. Common Stock position peaked at $660K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2023.

Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.